Profile data is unavailable for this security.
About the company
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
- Revenue in USD (TTM)237.00k
- Net income in USD-184.13m
- Incorporated1990
- Employees141.00
- LocationGeron Corp919 East Hillsdale Boulevard, Suite 250FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 473-7700
- Fax+1 (302) 655-5049
- Websitehttps://www.geron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 2.09bn | 355.00 | -- | 5.82 | -- | 12.78 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Recursion Pharmaceuticals Inc | 44.58m | -328.07m | 2.09bn | 500.00 | -- | 4.43 | -- | 46.84 | -1.57 | -1.57 | 0.2145 | 1.98 | 0.0658 | -- | 15.25 | 89,150.00 | -48.42 | -- | -56.49 | -- | 4.46 | -- | -735.99 | -- | -- | -- | 0.0025 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Sana Biotechnology Inc | 0.00 | -283.26m | 2.14bn | 328.00 | -- | 6.73 | -- | -- | -1.46 | -1.46 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -40.81 | -38.99 | -46.74 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Arvinas Inc | 78.50m | -367.30m | 2.22bn | 445.00 | -- | 3.34 | -- | 28.22 | -6.62 | -6.62 | 1.45 | 9.71 | 0.061 | -- | 157.00 | 176,404.50 | -28.35 | -22.01 | -36.10 | -26.47 | -- | -- | -464.71 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Maravai Lifesciences Holdings Inc | 288.95m | -119.03m | 2.22bn | 650.00 | -- | 5.31 | -- | 7.67 | -0.901 | -0.901 | 2.19 | 1.66 | 0.1533 | 3.15 | 2.99 | 444,530.80 | -7.34 | 12.67 | -9.75 | 15.46 | 48.52 | 74.79 | -47.89 | 37.32 | 7.41 | -0.3566 | 0.4134 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Kymera Therapeutics Inc | 78.59m | -146.96m | 2.23bn | 187.00 | -- | 5.11 | -- | 28.34 | -2.52 | -2.52 | 1.35 | 7.11 | 0.1333 | -- | 7.38 | 420,278.10 | -24.93 | -23.03 | -28.76 | -27.64 | -- | -- | -186.99 | -207.82 | -- | -- | 0.0065 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Intellia Therapeutics Inc | 36.28m | -481.19m | 2.24bn | 526.00 | -- | 2.06 | -- | 61.65 | -5.42 | -5.42 | 0.4106 | 11.29 | 0.0257 | -- | 1.80 | 68,963.88 | -34.11 | -31.34 | -37.31 | -34.53 | -- | -- | -1,326.51 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Dyne Therapeutics Inc | 0.00 | -235.94m | 2.24bn | 141.00 | -- | 17.51 | -- | -- | -3.94 | -3.94 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -100.10 | -52.81 | -120.31 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Guardant Health Inc | 563.95m | -479.45m | 2.26bn | 1.78k | -- | 14.24 | -- | 4.02 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Vericel Corp | 197.52m | -3.18m | 2.32bn | 314.00 | -- | 10.14 | 1,478.28 | 11.73 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Geron Corp | 237.00k | -184.13m | 2.32bn | 141.00 | -- | 8.68 | -- | 9,781.87 | -0.3246 | -0.3246 | 0.0004 | 0.455 | 0.0008 | -- | 0.0988 | 1,680.85 | -62.99 | -51.32 | -92.09 | -64.90 | -- | -- | -77,690.72 | -19,949.13 | -- | -- | 0.2484 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Vera Therapeutics Inc | 0.00 | -95.99m | 2.37bn | 51.00 | -- | 19.02 | -- | -- | -2.28 | -2.28 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.54 | -- | -74.10 | -- | -- | -- | -- | -- | -- | -- | 0.3291 | -- | -- | -- | -7.79 | -- | -- | -- |
| Denali Therapeutics Inc | 330.53m | -145.22m | 2.40bn | 445.00 | -- | 2.26 | -- | 7.25 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Avidity Biosciences Inc | 9.56m | -212.22m | 2.43bn | 253.00 | -- | 4.05 | -- | 254.05 | -2.90 | -2.90 | 0.131 | 6.32 | 0.0151 | -- | -- | 37,786.56 | -33.49 | -31.61 | -37.40 | -34.45 | -- | -- | -2,219.88 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Rhythm Pharmaceuticals Inc | 77.43m | -184.68m | 2.50bn | 226.00 | -- | 14.35 | -- | 32.27 | -3.19 | -3.19 | 1.34 | 2.86 | 0.2165 | 1.61 | 7.34 | 342,601.80 | -51.64 | -47.21 | -59.55 | -52.84 | 87.99 | -- | -238.52 | -681.38 | 5.43 | -- | 0.3847 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| TG Therapeutics Inc | 289.33m | 41.20m | 2.54bn | 264.00 | 74.47 | -- | 48.72 | 8.76 | 0.2205 | 0.2205 | 1.97 | -- | -- | -- | -- | 1,095,962.00 | -- | -62.87 | -- | -80.06 | 93.53 | -- | 14.24 | -405.03 | -- | 4.01 | -- | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Geron Corp's reporting currency: US Dollar USD
40.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2023 | 46.20m | 8.46% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 38.04m | 6.97% |
| Deep Track Capital LPas of 31 Dec 2023 | 29.58m | 5.42% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 27.41m | 5.02% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 25.63m | 4.69% |
| Millennium Management LLCas of 31 Dec 2023 | 14.73m | 2.70% |
| Geode Capital Management LLCas of 31 Dec 2023 | 10.94m | 2.00% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 10.30m | 1.89% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 9.48m | 1.74% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 7.03m | 1.29% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
